First-of-Its-Kind AI-Powered Solution Fully Automates Blood Morphology

While Complete Blood Counts (CBCs) have been automated for decades, laboratories still require a human in the loop during the Peripheral Blood Smear (PBS) review process. PBS review remains labor-intensive, complex, and plagued by inefficiencies and variability, resulting in bottlenecks that affect turnaround times, scalability, and ultimately, patient care. These issues are amplified given the ongoing staffing crisis in clinical laboratories. Global workforce shortages, long training cycles, and increased demand for diagnostic tests have left labs struggling to maintain performance. Now, the unveiling of a novel analyzer at ADLM 2025 ushers in a new era of lab automation, analyzing 10x more cells than the current standard of care in blood cell morphology, addressing the global laboratory staffing crisis, and accelerating hematology workflows and efficiencies

Scopio Labs (Parsippany, NJ, USA) is unveiling its groundbreaking Complete Blood Morphology (CBM) analyzer, bringing unprecedented scale, efficiency, and standardization to hematology through autonomous morphology analysis and reporting, one of the last remaining manual processes in diagnostics. CBM is built on top of Scopio's proprietary Full-Field technology, leveraging advanced computational imaging and AI-powered analysis to transform the current PBS review workflow into an autonomous, standardized, and clinically relevant process, analyzing 10x more cells than the current standard of care in blood cell morphology. Hematology labs currently utilizing Scopio's Full-Field PBS platform are already alleviating some of the pain points, while laying the essential groundwork for rapid CBM adoption, effectively future-proofing their operations.

"Our vision is to be the first to close the automation gap in hematology by developing a fully integrated and automated hematology process from CBC to final result," said Itai Hayut, CEO and Co-founder at Scopio Labs. "This isn't just a small step forward, it could potentially reshape the whole market by changing the workflow, the economics, and creating an entirely new market category. With CBM, the market can evolve from current digital lab solutions that help people make decisions, to a system that's designed to deliver fully automated results with the goal of eliminating the need for routine human morphology review altogether. Beyond that, we also believe that this technology will pave the way to developing accurate and consistent morphology-based biomarkers and diagnostic panels, which can be used for early detection and monitoring of disease directly from blood."

Related Links:
Scopio Labs